to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
HLA class II antigen presentation by prostate cancer cells.
Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.
Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.
HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition.
A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma.
Defects in HLA class II antigen presentation in B-cell lymphomas.
HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition.
Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma.
Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol.
Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.
Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.
Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.
Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.
HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy.
Multiple Defects Impair the HLA Class II Antigen Presentation Capacity of Burkitt Lymphoma.
Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis.
GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.
Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells.
HLA D Antigens